EFFICACY OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS BY LINE OF THERAPY IN THE PHASE 2B/3 SELECTION TRIALEFFICACY OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS BY LINE OF THERAPY IN THE PHASE 2B/3 SELECTION TRIAL

Laurent Peyrin-Biroulet  ¹     Iris Dotan  ²     Toshifumi Hibi  ³     Virginia Taliadouros  ⁴     Sally Zhao  ⁵     Jie Zhang  ⁵     Jeremy Hsieh  ⁵     Brian G. Feagan  ^6    
1 Nancy University Hospital, Nancy, France
² Rabin Medical Centre, Petah Tikva, Israel
³ Kitasato Institute Hospital, Kitasato University, Tokyo, Japan
⁴ Galapagos NV, Leiden, Netherlands
⁵ Gilead Sciences, Inc., Foster City, United States
⁶ Alimentiv Inc., London, Ontario, Canada

Topic
IBD, Immunology

Session
IBD: Clinical trials IV

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)